
Solving Matrix Suppression in Ultra-Trace NDSRI Analysis
When excipients suppress your nitrosamine signal, tailored method development reveals the truth. Resolian’s systematic approach overcomes matrix interference.

When excipients suppress your nitrosamine signal, tailored method development reveals the truth. Resolian’s systematic approach overcomes matrix interference.

Benzoyl peroxide can degrade to benzene during testing, creating false positives. Resolian’s antioxidant scavenger strategy prevents analytical artifacts.

Discover how Resolian’s green chemistry LC-HRMS method for extractables & leachables testing cut runtime by 37% and solvent use – without compromising sensitivity or quality.

Learn how Resolian achieved 0.8 ng/mL NMBA detection using HILIC-MS – overcoming reverse-phase limitations for ultra-trace nitrosamine analysis in drug products.
Discover how Resolian’s platform SFC-UV method analyzes vitamin E across multiple formulations – reducing organic solvent use while meeting GMP requirements.
Discover how Resolian increased LC-MS sensitivity by 438% using Design of Experiments – achieving required detection limits without new equipment investment.
False positives in nitrosamine testing can trigger unnecessary product recalls, regulatory scrutiny, and supply chain disruptions—threatening patient access to critical therapies. But what if the contamination isn’t from your product at all?

What would you do if you found a piece of unidentified material in your toothpaste today? Would you use it? Would you throw the whole tube away? Or, would you send a complaint to the company..?
Foreign matter is an issue across all industries – from food to medicines and consumer products

Our Flow Cytometry team have designed a sample processing package that solves the logisitcally challenges with samples.

CASE STUDY – Addressing ADC Regulatory Challenges by Providing Validated Assays for Multi-Domain Proteins…
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.